Join today and have your say! It’s FREE!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}

Join today with :

or

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Sign in with existing account
Please Try Again
{{ error }}

Sign In With :

or

Password Hint : {{passwordHint}}
Forgot Password?
Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Histogenics Corporation OCGN

Ocugen Inc is a clinical stage biopharmaceutical company. It is focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. Ocugen offers a diversified ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules and targets a broad range of high-need retinal and ocular surface diseases.

View modes: 

merger & acquisitions

and its a symbol &name change,to OCGN,so glta.  rate and reply

tough day

on the markets today,so glta.  rate and reply

still holding this stock

it's still flat lining for a long time but still holding and waiting for a breakout to the upside,so glta.  rate and reply

still holding this stock

starting to pick up bigtime,so glta.  rate and reply

RE:next .24

I am having a change of heart. iam out.  rate and reply

next .24

Lewis Michael Relationship as filed with regulators: Director Latest filing date: February 11, 2019 NON-DERIVATIVE   Indirect Ownership: Other     Common Stock 5,258,859 DERIVATIVE...read more

next .24

Rakin Kevin Relationship as filed with regulators: Director Latest filing date: February 11, 2019 NON-DERIVATIVE   Direct Ownership     Common Stock 418,639   Indirect...read more

Rakin Kevin

owns 5,258,859  rate and reply

loading up big time with

this stock,using dollar cost averaging for my purchase prices,so glta shareholders today but we should see a breakout to the upside soon as it seems to be way oversold.  rate and reply

added more of this one

using dollar cost averaging and will keep it for a few months to give this stock a chance,so glta.  rate and reply

adding more shares here

at 22 cents per share,the bottom is past,so glta shareholders.  rate and reply

looks pretty steady here at

these prices,so glta as maybe the worst is over.  rate and reply

strong technical chart here

it is so easy for the old,rich and coolfooldumbguy to make money in the good old U.S.A. glta.  rate and reply

FYI

Histogenics Corporation (NASDAQ: HSGX) is a clinical-stage company, focuses on the development of restorative cell therapies. The company offers NeoCart, a tissue implant, which is in Phase III...read more

RE:Sector news

What's the insider ownership in HSGX? thanks.  rate and reply

Sector news

I don't know whether HSGX is a takeover target but the sector news is interesting. Predictive Technology Group (PRED)  yesterday acquired Regenerative Medical Technologies, Inc. (RMT...read more

RE:adding more shares here

Can't believe no one else seems to see this ticking time bomb.. This will end very well for us  rate and reply

adding more shares here

at these prices,so glta.  rate and reply

adding more shares here

at this price,it is cheap and should perform well into the future,so glta.  rate and reply

nice play for me

we will see friday as to what's going on here,so glta.  rate and reply

×

StockTalk
Get our FREE StockTalk Investor Guides by sector as they are released!

Stay on top of sector specific news, get industry leaders insights and our best content, delivered to your email.

You are already a member! Please enter your password to sign in.